Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for the treatment of osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.” Show notes are available at [ Ссылка ] — for helpful links or to hear more podcast episodes, visit [ Ссылка ]
